Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3475200 | 0.87 | P2RX7 (0.49) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL3473435 | 0.85 | SMN1; SMN2 (0.50) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL3474969 | 0.84 | CA12 (0.49) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL3471908 | 0.82 | SMN1; SMN2 (0.46) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL3473081 | 0.82 | TDP1 (0.48) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL13876177 | 0.81 | EPHX2 (0.61) | EPHX2P2RX7GAAHTT | |
| SCHEMBL3473076 | 0.80 | SMN1; SMN2 (0.47) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL3473937 | 0.80 | DGAT2 (0.49) | EPHX2P2RX7GAAHTTSMN1; SMN2 | |
| SCHEMBL2265219 | 0.77 | EPHX2 (0.57) | EPHX2P2RX7GAAHTTSMN1; SMN2 | |
| SCHEMBL3475524 | 0.75 | EPHX2 (0.66) | EPHX2P2RX7GAAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | GLAXOSMITHKLINE LLC | 2010-12-23 | — | — | US | disclosed |
| EP-2240021-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009097474-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | EPHX1, NCEH1, PCSK9 | EPHX2 5/4885CA12 4471/4885CA1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.